An investigation on behalf of investors, who currently hold shares of Shire plc (NASDAQ: SHPG), was announced concerning whether the takeover of Shire plc. by Takeda Pharmaceutical Company is unfair to NASDAQ: SHPG stockholders.

The investigation by a law firm concerns whether certain officers and directors of Shire plc breached their fiduciary duties owed to NASDAQ: SHPG investors in connection with the proposed acquisition.

On May 8, 2018, Shire plc (NASDAQ: SHPG) and Takeda Pharmaceutical Company Limited (Takeda) announced that they reached agreement on the terms of a recommended offer pursuant to which Takeda Pharmaceutical Company Limited will acquire the entire issued and to be issued ordinary share capital of Shire plc. Under the terms of the transaction, Shire shareholders will receive $30.33 in cash and either 0.839 Takeda shares or 1.678 Takeda American Depositary Shares for each share of Shire they own.

However, the investigation concerns whether the offer is unfair to Shire plc (NASDAQ: SHPG stockholders. More specifically, the investigation concerns whether the Shire plc (NASDAQ: SHPG Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.